ORIC Pharmaceuticals Grants 188,400 Inducement Awards to Six New Hires

SOUTH SAN FRANCISCO and SAN DIEGO — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced on 1 October 2026 that it granted 161,550 non-qualified stock options and 26,850 restricted stock units to six new non-executive employees. The company disclosed the awards in a public filing carried on 2 October 2026. The total award count across both instruments reaches 188,400 units of equity, spread across a workforce addition the company said began in September 2026.

The grants were made under ORIC's 2022 Inducement Equity Incentive Plan and were approved by the Compensation Committee of the company's Board of Directors, as required by Nasdaq Rule 5635(c)(4).

Context — why inducement grants matter for a clinical-stage biotech

Inducement grants sit outside the shareholder-approval requirement that normally governs equity plans. Nasdaq Rule 5635(c)(4) allows a listed company to issue stock options and restricted stock units to new employees without a shareholder vote, provided the awards serve as a material inducement to employment. ORIC's Compensation Committee approved the grants under that exemption.

The mechanism matters because it lets a company hire without waiting for an annual meeting. For a clinical-stage oncology developer competing for specialist talent, the ability to move quickly on compensation is a practical hiring tool.

The report does not disclose the grant-date closing price used to set the option exercise price. It does not name the six employees, their roles, or the specific teams they joined. It does not state the dollar value of the awards at grant. The company also did not disclose how the new hires compare with headcount at the start of 2026.

What the report does give is the vesting architecture. Stock options vest 25% on the first anniversary of the 1 October 2026 grant date, with the remaining shares vesting in equal monthly instalments of one thirty-sixth over the following three years. That produces a full four-year vesting runway from the grant date.

The restricted stock units follow a simpler schedule: one-third vests on each of the first three anniversaries. All awards remain subject to the recipient's continued employment or service through each vesting date.

The awards carry no performance conditions in the disclosed terms. Vesting is time-based only, which means the equity becomes payable regardless of clinical milestones, regulatory progress, or the company's share price at each vesting date.

Data — what the numbers show

The headline figures are 161,550 stock options and 26,850 restricted stock units. Options account for roughly 85.7% of the total award count, with RSUs making up the remaining 14.3%.

Metric	Value
Grant date	1 October 2026
Disclosure date	2 October 2026
New non-executive employees	6
Non-qualified stock options	161,550
Restricted stock units	26,850
Total awards	188,400
Option vesting	25% at year one, 1/36th monthly thereafter
RSU vesting	1/3rd on each of first three anniversaries

Dividing the totals by the six recipients gives an average of about 26,925 options and 4,475 RSUs per new hire, though the report does not confirm that the awards were split evenly. Individual allocations may differ.

The option exercise price equals the closing price of ORIC's common stock on the grant date, the company said. The report does not state that closing price, so the strike level and the aggregate grant-date value cannot be calculated from the disclosure alone.

There is no peer comparison in the report. The company did not benchmark the award size against other clinical-stage oncology issuers, and it did not disclose its total shares outstanding, which would be needed to express the grants as a percentage of the float.

What the structure does reveal is a deliberate mix. Options dominate the package, tying the bulk of the value to share-price appreciation above the grant-date close. The RSU tranche delivers value on a fixed schedule regardless of price direction, which gives recipients a floor on part of the award.

The first vesting events land in October 2027 for the option tranche and the first RSU third. Nothing vests before that date under the disclosed terms.

Analysis — what it means for markets, sectors, and tickers

The grants are a hiring signal, not a capital-markets event. Issuing equity to new employees does not raise cash, retire debt, or alter the clinical pipeline. For ORIC specifically, the awards dilute existing holders modestly, though the report gives no share count to size that dilution.

The second-order read is about talent competition in oncology. ORIC's stated focus is mechanisms of therapeutic resistance, with two clinical-stage candidates: rinzimetostat, an allosteric PRC2 inhibitor via the EED subunit in development for prostate cancer, and enozertinib, a brain-penetrant EGFR inhibitor targeting exon 20 insertion and atypical mutations in NSCLC. Both programmes sit in crowded development spaces, where specialist scientists and clinical operators are the scarce input.

Using inducement grants rather than a shareholder-approved plan shortens the hiring cycle. That is the practical advantage of Rule 5635(c)(4), and it is why clinical-stage issuers lean on it when they are adding staff between annual meetings.

The counter-argument is dilution discipline. Inducement awards bypass a shareholder vote by design, so investors cannot register disapproval at the ballot. A single grant of 188,400 units is small in isolation, but the exemption can be used repeatedly, and the report does not disclose cumulative inducement issuance under the 2022 plan.

A second limitation is information asymmetry. Without the grant-date closing price, the number of shares outstanding, or the identity and seniority of the recipients, outside holders cannot assess the award's economic weight. The disclosure satisfies the Nasdaq requirement without answering the sizing question.

Positioning around the news is likely to be minimal. This is a routine compensation filing for a small-cap clinical-stage name, and it carries no read-through to the company's trial timelines or cash runway. Flow into or out of ORIC is more likely to track pipeline news than an inducement grant.

Outlook — what to watch next

The next scheduled vesting milestone is October 2027, when 25% of the option shares and one-third of the RSUs vest, provided recipients remain employed. Before that, the company's quarterly filings will show whether inducement issuance continues and at what pace.

Investors watching ORIC should track clinical disclosures on rinzimetostat in prostate cancer and enozertinib in NSCLC, since those programmes drive the equity story rather than compensation mechanics. The report gives no trial readout dates, so the timing of those catalysts is not established here.

On the compensation side, the items to monitor are the grant-date closing price when it appears in future filings, the cumulative number of shares issued under the 2022 Inducement Equity Incentive Plan, and whether the company returns to the inducement exemption for further hiring. Each of those would let holders size the dilution that this disclosure leaves open.

Frequently Asked Questions

What does an inducement grant under Nasdaq Rule 5635(c)(4) mean for retail investors?

It means the company issued equity to new employees without putting the award to a shareholder vote. Nasdaq permits this when the grant is a material inducement to accepting employment. For retail holders, the practical effect is share dilution, though the report does not give a share count, so the size of that dilution relative to ORIC's total outstanding stock cannot be calculated from this disclosure.